WNT5A and endometrium adenocarcinoma: Singleton et al. found that Wnt5a and FZD5 were downregulated by bisphenol-A (an estrogen receptor agonist) and estradiol.14,15 These findings are concordant with the physiopathology of type I endometrial adenocarcinoma.